PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 224 filers reported holding PDL BIOPHARMA INC in Q2 2014. The put-call ratio across all filers is 0.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $104,000 | -36.6% | 41,972 | -41.8% | 0.00% | -40.0% |
| Q1 2017 | $164,000 | +51.9% | 72,147 | +42.1% | 0.01% | +66.7% |
| Q4 2016 | $108,000 | +3.8% | 50,765 | +63.2% | 0.00% | +50.0% |
| Q3 2016 | $104,000 | +55.2% | 31,100 | +54.5% | 0.00% | 0.0% |
| Q1 2016 | $67,000 | -84.8% | 20,130 | -83.8% | 0.00% | -71.4% |
| Q4 2015 | $440,000 | +368.1% | 124,354 | +564.6% | 0.01% | +250.0% |
| Q3 2015 | $94,000 | -68.5% | 18,711 | -59.7% | 0.00% | -60.0% |
| Q2 2015 | $298,000 | -10.2% | 46,413 | +7.8% | 0.01% | 0.0% |
| Q4 2014 | $332,000 | +5.4% | 43,061 | +2.3% | 0.01% | -16.7% |
| Q3 2014 | $315,000 | -27.8% | 42,108 | -6.7% | 0.01% | -14.3% |
| Q2 2014 | $436,000 | +36.2% | 45,154 | +17.0% | 0.01% | +75.0% |
| Q1 2014 | $320,000 | +144.3% | 38,596 | +148.7% | 0.00% | +300.0% |
| Q4 2013 | $131,000 | -86.4% | 15,519 | -87.2% | 0.00% | -91.7% |
| Q3 2013 | $965,000 | – | 121,087 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |